Novel Thrombolytics for Acute Ischemic Stroke: Challenges and Opportunities.

about

Desmoteplase for Acute Ischemic Stroke within 3 to 9 Hours after Symptom Onset: Evidence from Randomized Controlled Trials

P2860

Q36145434-7C25F6D3-94C0-48FC-B68B-915642C50624

P2860

Novel Thrombolytics for Acute Ischemic Stroke: Challenges and Opportunities.

Item

http://www.wikidata.org/entity/Q38917550

description

2016 nî lūn-bûn

@nan

2016年の論文

@ja

2016年学术文章

@wuu

2016年学术文章

@zh-cn

2016年学术文章

@zh-hans

2016年学术文章

@zh-my

2016年学术文章

@zh-sg

2016年學術文章

@yue

2016年學術文章

@zh

2016年學術文章

@zh-hant

name

Novel Thrombolytics for Acute Ischemic Stroke: Challenges and Opportunities.

@en

type

Item

label

Novel Thrombolytics for Acute Ischemic Stroke: Challenges and Opportunities.

@en

prefLabel

Novel Thrombolytics for Acute Ischemic Stroke: Challenges and Opportunities.

@en

P1476

Novel Thrombolytics for Acute Ischemic Stroke: Challenges and Opportunities.

@en

P2093

Aliona Nacu

http://www.w3.org/2001/XMLSchema#string

Christopher E Kvistad

http://www.w3.org/2001/XMLSchema#string

Lars Thomassen

http://www.w3.org/2001/XMLSchema#string

Nicola Logallo

http://www.w3.org/2001/XMLSchema#string

P2860

Recombinant tissue plasminogen activator for acute ischaemic stroke: an updated systematic review and meta-analysis

Vampire bat salivary plasminogen activator (desmoteplase): a unique fibrinolytic enzyme that does not promote neurodegeneration

A randomized trial of tenecteplase versus alteplase for acute ischemic stroke

Tissue plasminogen activator for acute ischemic stroke

Phase IIB/III trial of tenecteplase in acute ischemic stroke: results of a prematurely terminated randomized clinical trial

A pilot dose-escalation safety study of tenecteplase in acute ischemic stroke.

The Norwegian tenecteplase stroke trial (NOR-TEST): randomised controlled trial of tenecteplase vs. alteplase in acute ischaemic stroke.

Vampire bat plasminogen activator DSPA-alpha-1 (desmoteplase): a thrombolytic drug optimized by natural selection.

Safety and efficacy of desmoteplase given 3-9 h after ischaemic stroke in patients with occlusion or high-grade stenosis in major cerebral arteries (DIAS-3): a double-blind, randomised, placebo-controlled phase 3 trial.

Pharmacokinetics and pharmacodynamics of tenecteplase in fibrinolytic therapy of acute myocardial infarction.

P2888

s40263-015-0307-2

P304

101-108

http://www.w3.org/2001/XMLSchema#string

P31

scholarly article

P356

10.1007/S40263-015-0307-2

http://www.w3.org/2001/XMLSchema#string

P433

http://www.w3.org/2001/XMLSchema#string

P478

http://www.w3.org/2001/XMLSchema#string

P577

2016-01-21T00:00:00Z

http://www.w3.org/2001/XMLSchema#dateTime

P698

26798040

http://www.w3.org/2001/XMLSchema#string

P921

thrombolysis

Novel Thrombolytics for Acute Ischemic Stroke: Challenges and Opportunities.

about

P2860

P2860

Novel Thrombolytics for Acute Ischemic Stroke: Challenges and Opportunities.

description

name

type

label

prefLabel

P1433

P1476

P2093

P2860

P2888

P304

P31

P356

P433

P478

P577

P698

P921

P356

P1433

P1476

P2093

P2860

P2888

P304

P31

P356

P433

P478

P577

P698

P921